AIMS This study aimed at evaluating the DNA vaccination efficacy of Leishmania major-derived MAPK10 against Leishmania donovani infection. METHODS AND RESULTS MAPK10 is one of the 15 mitogen-activated protein kinases (MAPKs) of Leishmania major. Herein, we expressed the gene through a mammalian vector and tested whether priming with this gene would offer protection against L donovani infection. We report that LmjMAPK10 DNA vaccination using a mammalian expression vector significantly reduces the parasite burden. The protection is accompanied by host-protective T-cell functions, TH 1-type cytokines and elevated leishmanial antigen-specific IgG2a isotype response. T-cell response to the L donovani/challenge infection is associated with increase in IL-12 and IFN-γ, but reduced IL-10 and IL-4 production. CONCLUSIONS LmjMAPK10 is cross-protective against L donovani infection.

中文翻译：

---

LmjMAPK10提供了针对多形利什曼原虫感染的保护作用。

目的本研究旨在评估利什曼原虫主要来源的MAPK10的DNA疫苗接种疫苗对利什曼原虫donovani感染的功效。方法和结果MAPK10是利什曼原虫（Leishmania major）的15种丝裂原活化蛋白激酶（MAPK）之一。在本文中，我们通过哺乳动物载体表达了该基因，并测试了用该基因引发是否可以提供抗L donovani感染的保护。我们报告说，使用哺乳动物表达载体的LmjMAPK10 DNA疫苗接种显着降低了寄生虫负担。该保护伴随有宿主保护性T细胞功能，TH 1型细胞因子和利什曼原虫抗原特异性IgG2a同种型应答升高。T细胞对L多诺维尼/挑战感染的反应与IL-12和IFN-γ的增加有关，但IL-10和IL-4的产生减少。